Clinical Trial Update: Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of combining apatinib with transarterial chemoembolization (TACE) in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization | Phase 2 | Status: UNKNOWN